Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02004704 · ClinicalTrials.gov registry record · Phase 2
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT02004704 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 25 participants.
The verdict
NCT02004704, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The primary objective of this study was to obtain data regarding the safety of olipudase alfa in participants with acid sphingomyelinase deficiency (ASMD) who were exposed to long term treatment with olipudase alfa. The secondary objectives of this study were to obtain data regarding the efficacy of olipudase alfa and to characterize olipudase alfa pharmacodynamics (PD) and pharmacokinetics (PK) following long-term administration.
Interventions
- DRUG GZ402665
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-12-04 |
| Est. Completion | 2023-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02004704
The ClinicalTrials.gov registry entry for NCT02004704 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GZ402665 is the first listed.
NCT02004704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02004704 about?
NCT02004704 is a clinical study titled "A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency". The primary objective of this study was to obtain data regarding the safety of olipudase alfa in participants with acid sphingomyelinase deficiency (ASMD) who were exposed to long term treatment with olipudase alfa. The secondary objectives of this study were to obtain data regarding the efficacy o...
What is the current status of trial NCT02004704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2013-12-04. Estimated completion is 2023-09-06.
What interventions are being tested in trial NCT02004704?
The interventions under investigation include: GZ402665 (DRUG).
Who is sponsoring clinical trial NCT02004704?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.